Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback